EUCTR2014-005363-33-ES进行中（未招募）不适用
Reducing Micro Vascular dysfunction In revascularized STEMI patients by off-target properties of ticagrelor - REDUCE-MVI
VU university medical center0 个研究点目标入组 110 人开始时间: 2016年2月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provision of informed consent
- •2. Patients presenting with STEMI <12 hours
- •3. Successful PCI of the infarct-related vessel with a modern DES
- •4. Intermediate stenosis in non-infarct-related vessel (50-90%)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 70
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •1. history of myocardial infarction
- •2. Participation in another clinical study with an investigational product
- •during the preceding 30 days
- •3. history of cerebrovascular accident (CVA) or 'transient ischaemic
- •attack' (TIA)
- •4. History of intracranial haemorrhage
- •5. indication or use of oral anticoagulant therapy (i.e. acenocoumarol)
- •6. severe liver dysfunction (Child-Pughscore 10?15)
- •7. congestive heart failure
- •8. cardiogenic shock
- •9. left ventricular ejection fraction < 35%
- •10. bleeding diathesis
- •11. age ? 75 or < 18
- •12. body weight < 60 kg
- •14. coagulation disorders
- •15. severe pulmonary disease
- •16. pregnancy and breast feeding
- •17. limited life expectancy
- •18. platelet count < 100 000/mm3
- •19. history of drug addiction or alcohol abuse in the past 2 years
- •20. need for chronic nonsteroidal anti-inflammatory drug
- •21. creatinine clearance <30 mL/min or dialysis
- •22. chronic total occlusion (CTO)
- •23. Left main disease
- •24. allergy or contra-indication for ticagrelor or prasugrel
- •25. Contra-indication for adenosine
- •26. Patients unable to be followed on-site
- •27. Unable to undergo or contra-indications for MRI
- •28. Contra-indication for DES
- •29. Inability to obtain informed consent
研究者
相似试验
进行中（未招募）
1 期
Discovering beneficial properties of ticagrelor in acute myocardial infarctioST elevation myocardial infarction (STEMI)EUCTR2014-005363-33-NLVU university medical center110
已完成
不适用
Reducing Micro Vascular dysfunction In revascularized STEMI patients by off-target properties of ticagrelorMyocardial infarctionNL-OMON44678Vrije Universiteit Medisch Centrum110
招募中
不适用
Post-operative exercise training for peripheral arterial diseasePeripheral arterial diseaseACTRN12616001232426niversity of the Sunshine Coast30
招募中
不适用
Reduced Microvascular Blood Volume as a Driver of Coronary Microvascular Disease in Patients with Non Obstructive Coronary Artery DiseaseNL-OMON49617Vrije Universiteit Medisch Centrum61
招募中
不适用
Reduced Microvascular Blood Volume as a Driver of Coronary Microvascular Disease in Patients with Non-Obstructive Coronary Artery Disease: The MICORDIS-studyNL-OMON23861Amsterdam UMC56